• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
COVID-19 Testing

Vaccines in Pregnant and Lactating Women: Is Immune Response Similar to that of Non-Pregnant Patients?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Gray et al. (AJOG, 2021) evaluated the immunogenicity (ability to provoke an immune response) and reactogenicity (ability to provoke expected adverse reactions) of COVID-19 mRNA vaccination in pregnant and lactating women vs non-pregnant controls

METHODS:

  • Prospective cohort study
  • Participants (≥18 years)
    • Pregnant or nursing
    • Non-pregnant and of reproductive age
  • Exposure
    • COVID-19 vaccine (Pfizer or Moderna mRNA vaccine)
  • Study design
    • SARS-CoV-2 IgG, IgA and IgM were quantified in sera and breastmilk
    • Timepoints: Baseline | Second vaccine dose | 2 to 6 weeks post second vaccine | Delivery
    • Titers compared to those of pregnant women 4 to 12 weeks following natural infection (ELISA platform used)
    • Neutralizing antibody titers were evaluated for a participant subset who delivered
    • Post-vaccination symptoms were assessed via questionnaire
    • Differences between groups was assessed, including using statistical tools to account for multiple sampling

RESULTS:

  • 131 vaccine recipients | Cord blood obtained from 10 deliveries
    • Pregnant: 84
    • Lactating: 31
    • Non-pregnant: 16
  • Compared to non-pregnant women, pregnant and lactating women had similar vaccine-induced antibody titers (p=0.24)
    • Pregnant: Median (IQR) 5.59 (4.68 to 5.89]
    • Lactating: Median (IQR) 5.74 (5.06 to 6.22)
    • Non-pregnant: Median (IQR) 5.62 (4.77 to 5.98)
  • All vaccine-induced titers were significantly higher than those induced by natural SARS-CoV-2 infection during pregnancy (p<0.0001)
  • Vaccine-generated antibodies were present in all umbilical cord blood and breastmilk samples
    • IgG breast milk levels rose concurrently with maternal serum levels
  • While neutralizing antibody titers were lower in umbilical cord vs maternal sera, the difference was not statistically significance (p=0.05)
    • Umbilical cord sera: median (IQR) 52.3 (11.7 to 69.6)
    • Maternal sera: 104.7 (61.2 to 188.2)
  • Second vaccine dose increased SARS-CoV-2-specific IgG but not IgA, such that IgG was the dominant serum antibody for all groups by 2 weeks post-second vaccine
  • Reactogenicity was similar across pregnant, lactating and non-pregnant groups

CONCLUSION:

  • Pregnant and lactating women who received either of the COVID-19 mRNA vaccines experienced robust vaccine-induced immunity
    • Immunogenicity and reactogenicity in pregnancy were similar to that seen in non-pregnant women
  • The vaccine-induced immunity response was significantly greater than the immune response caused by natural SARS-CoV-2 infection
  • Immune transfer to neonates could occur via breastmilk or placenta
  • While the authors are clear that this study does not address possible fetal risks, they conclude

While the absolute risk of severe COVID-19 is low in pregnant women, pregnancy is a risk factor for severe disease

These data provide a compelling argument that COVID-19 mRNA vaccines induce similar humoral immunity in pregnant and lactating women as in the non-pregnant population

Learn More – Primary Sources:

COVID-19 vaccine response in pregnant and lactating women: a cohort study

Get Mobile-Friendly COVID-19 Research Summaries with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Testing Posts
Next >

Related ObG Topics:

Covid-19 Vaccines, Pregnancy & Fertility
Guidance on COVID-19 Vaccine Including Pregnancy
Maternal Outcomes and COVID-19: Results from a Large US-Based Cohort
Safety and Efficacy Data of BNT162b2 COVID-19 Vaccine
The Moderna Vaccine: Study Results Presented to ACIP CDC Committee

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site